LNP023 HYDROCHLORIDE SALT ( DrugBank: - )

---

5 diseases

ID	Disease name (Link within this page)	Number of trials
61	Autoimmune hemolytic anemia	0
62	Paroxysmal nocturnal hemoglobinuria	0
66	IgA nephropathy	0
109	Atypical hemolytic uremic syndrome	0
222	Primary nephrotic syndrome	0

61. Autoimmune hemolytic anemia

---

Clinical trials : 137 /  Drugs : 127 - (DrugBank : 55) / Drug target genes : 26 - Drug target pathways : 153

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

62. Paroxysmal nocturnal hemoglobinuria

---

Clinical trials : 271 /  Drugs : 163 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 106

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

66. IgA nephropathy

---

Clinical trials : 255 /  Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

109. Atypical hemolytic uremic syndrome

---

Clinical trials : 115 /  Drugs : 37 - (DrugBank : 7) / Drug target genes : 3 - Drug target pathways : 10

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

222. Primary nephrotic syndrome

---

Clinical trials : 285 /  Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries